• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Data supports GI Dynamics’ type 2 diabetes treatment

July 14, 2022 By Sean Whooley

GI Dynamics LogoGI Dynamics announced today that results from a registry for its EndoBarrier for type 2 diabetes were positive.

Data from use of the EndoBarrier within the National Health Service (NHS) in the UK were presented by Dr. Robert Ryder of City Hospital (Birmingham, UK) at the American Diabetes Association Scientific Sessions last month, according to a news release.

Boston-based GI Dynamics designed its EndoBarrier endoscopically delivered device therapy as a non-surgical, alternative treatment for type 2 diabetes and obesity for patients who do not have adequate control of their conditions through their current medication and lifestyle. Previous studies have demonstrated that the device met trial safety and efficacy endpoints.

GI Dynamics’ ABCD worldwide EndoBarrier registry, led by Dr. Ryder, collected data from 33 centers in nine countries, with data entered on 1,001 patients as of December 2021.

“In these analyses, the data highlight clinically significant reductions in HbA1c showing 1.3% absolute mean reduction Worldwide and a 1.9% mean reduction in the UK, even though there were many patients without diabetes or with good glycemic control. In addition, we also saw a 13.3kg mean reduction in weight worldwide and 17.3kg mean reduction in the UK study along with improved associated cardiovascular metrics and systolic blood pressure,” Ryder said in a news release. “When considering the overall clinical benefit of EndoBarrier treatment with the acceptable risk profile, the data combines to present a positive case for treatment of patients with type 2 diabetes and obesity.”

Filed Under: Clinical Trials, Diabetes, Surgical Tagged With: GI Dynamics

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS